Ocugen, Inc.
Bioscience Park Center
12635 E Montview Boulevard
Aurora
Colorado
80045
United States
Tel: 720-859-3549
Website: http://ocugen.com/
212 articles about Ocugen, Inc.
-
Ocugen CEO to Present at H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference
8/12/2022
Ocugen, Inc announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer and Co-Founder of Ocugen, will deliver a virtual presentation at the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference on August 17.
-
Ocugen Provides Business Update & Second Quarter 2022 Financial Results Conference Call and Webcast Today at 8:30 a.m. ET
8/5/2022
Ocugen, Inc. today reported financial results for the quarter ended June 30, 2022, and provided a general business update.
-
Ocugen To Host Conference Call on Friday, August 5 at 8:30 a.m. ET to Discuss Business Updates and Second Quarter 2022 Financial Results
7/29/2022
Ocugen, Inc. today announced that it will host a conference call and simultaneuous webcast to discuss the Company’s second quarter 2022 financial results and provide a business update at 8:30 a.m. ET on Friday, August 5, 2022.
-
Ocugen Announces Publication of Positive Results of COVID-19 Vaccine Trial for Children 2-18 in The Lancet Infectious Diseases
6/21/2022
Ocugen’s partner Bharat Biotech’s Phase 2/3 study of COVAXIN™ (BBV152) in 526 children showed safety, efficacy, and superior response to that shown in adults.
-
The week began with positive updates in the vaccine development space against various infectious diseases from Emergent, Merck, Affinivax and Ocugen.
-
Ocugen Named Among Philadelphia’s ‘2022 Best Places to Work’
6/14/2022
Ocugen, Inc . (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologicals, and vaccines, today announced that the Philadelphia Business Journal named the Company among the “2022 Best Places to Work.”
-
Ocugen, Inc. Announces Issuance of U.S. Patent for Treating Retinal Degenerative Diseases Using Gene TherapyIssuance of U.S. Patent No. 11,351,225 Further Enhances Ocugen’s Gene Therapy Intellectual Property Portfolio
6/13/2022
Ocugen, Inc. (NASDAQ:OCGN), a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel gene and cell therapies, biologicals, and vaccines, today announced that on June 7, 2022, the United States Patent and Trademark Office (“USPTO”) issued U.S. Patent No. 11,351,225, which is directed to methods for preventing or treating an ocular disease or disorder associated with a retinal degenerative disease.
-
Ocugen, Inc. to Present at BIO International Convention 2022
6/9/2022
Ocugen, Inc. announced that Michael Shine, Ocugen’s Senior Vice President, Commercial, will present at the 2022 BIO International Convention being held in San Diego, California, from June 13-16, 2022.
-
Ocugen introduced NeoCart, which is designed to repair full-thickness lesions of the knee cartilage in adults, as a Phase III cell therapy platform technology.
-
Ocugen Announces New Cell Therapy Program Following FDA Regenerative Medicine Advanced Therapy (RMAT) Recognition
5/24/2022
Ocugen, Inc. today announced that it is diversifying its innovative pipeline by introducing a Phase 3, cell therapy platform technology called NeoCart® (autologous chondrocyte-derived neocartilage).
-
Ocugen, Inc. to Present at H.C. Wainwright Global Investment Conference
5/23/2022
Ocugen, Inc. (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene therapies, biologicals and vaccines, today announced that Dr. Shankar Musunuri, Chairman, CEO and Co-Founder of Ocugen, will participate in an in-person fireside chat at the H.C. Wainwright Global Investment Conference, on May 24, 2022, at 1:30pm ET in Miami Beach, Florida.
-
Ocugen Announces FDA Removes Clinical Hold on Phase 2/3 Clinical Trial for COVAXIN™ (BBV152)Dosing to Resume Immediately
5/23/2022
Ocugen, Inc. announced that the U.S. Food and Drug Administration lifted the clinical hold on the Company’s Phase 2/3 clinical trial, OCU-002, for COVAXIN™.
-
Lifting the clinical hold will allow Ocugen to continue to assess the vaccine in its ongoing study and potentially support its efforts to achieve EUA or full approval.
-
Ocugen Provides Business Update and First Quarter 2022 Financial Results
5/6/2022
Ocugen, Inc. reported first quarter 2022 financial results along with a general business update.
-
Ocugen to Host Conference Call on Friday, May 6 at 8:30 a.m. ET to Provide Business Update and Discuss First Quarter 2022 Financial Results
5/2/2022
Ocugen, Inc. today announced that it will host a conference call to provide a business update and discuss its first quarter 2022 financial results at 8:30 a.m. ET on Friday, May 6, 2022.
-
A roundup of last week's top clinical trial updates and news.
-
Ocugen, Inc. to Present Preclinical Results at The Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting
4/29/2022
Ocugen, Inc. (NASDAQ: OCGN), a biotechnology company focused on discovering, developing and commercializing novel gene therapies, biologicals and vaccines, today announced two presentations on the company’s research into the development of a modifier gene therapy to treat dry age-related macular degeneration (AMD), and a novel biologic to treat wet-AMD and diabetic macular edema (DME) at The Association for Research in Vision and Ophthalmology’s (ARVO) 2022 Annual Meeting.
-
The DSMB for Ocugen's Phase I/II trial of OCU400, a gene therapy in development for Retinitis Pigmentosa (RP), recommended the study proceed with enrolling more patients.
-
Ocugen, Inc. Announces Positive DSMB Recommendation for OCU400-101 Clinical Trial
4/25/2022
Ocugen, Inc. announced today that the independent Data and Safety Monitoring Board (DSMB) for its Phase 1/2 clinical trial of OCU400 reviewed safety data based on dosing to date and recommended that the study proceed with enrolling additional subjects.
-
Ocugen, Inc. to Present at NobleCon18
4/19/2022
Ocugen, Inc. announces that Dr. Shankar Musunuri, Chairman, CEO and Co-Founder of Ocugen, will present on-location at NobleCon18 - Noble Capital Markets’ Eighteenth Annual Investor Conference.